MDT-AP-3249
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- age_years
- 35
- sex
- M
- new_clusters
- S2
- umap1_2d
- 0.389720775
- umap2_2d
- -9.266649241
- umap1_3d
- -4.342218726
- umap2_3d
- -1.993471377
- umap3_3d
- 6.055488236
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.490
- ANDROGEN_RESPONSE+0.420
- MTORC1_SIGNALING+0.420
- E2F_TARGETS+0.410
- G2M_CHECKPOINT+0.410
- MITOTIC_SPINDLE+0.410
- HEDGEHOG_SIGNALING+0.390
- MYC_TARGETS_V1+0.390
- UNFOLDED_PROTEIN_RESPONSE+0.340
- GLYCOLYSIS+0.320
Top 10 suppressed
- KRAS_SIGNALING_DN-0.330
- DNA_REPAIR-0.160
- SPERMATOGENESIS-0.110
- ALLOGRAFT_REJECTION-0.100
- XENOBIOTIC_METABOLISM-0.100
- MYOGENESIS-0.090
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.070
- COAGULATION-0.060
- ESTROGEN_RESPONSE_LATE-0.050
- INTERFERON_ALPHA_RESPONSE-0.040
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934788 | — | — | 0.834 |
| 2 | TCGA-H7-8502-01A-11R-2403-07 | — | — | 0.834 |
| 3 | BDEB76B7-B7E0-4058-82A2-77E93748C936 | — | — | 0.820 |
| 4 | SJEPD031429_D1.RNA-Seq | EPN | EPN Tumor | 0.816 |
| 5 | TCGA-77-7337-01A-21R-2045-07 | — | cohortSQ1 | 0.815 |
| 6 | SRR9879279 | — | cohortA1 | 0.811 |
| 7 | 34229BDA-4BF2-4537-A663-15896F6E269A | — | — | 0.807 |
| 8 | 8EFB3C39-094A-4F91-8B8D-EE8A32AC7E1F | — | — | 0.798 |
| 9 | 07D10802-F79E-495E-B842-895C444CA439 | — | — | 0.797 |
| 10 | SRR934827 | — | — | 0.794 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.490 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.420 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.420 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.410 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.410 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.410 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.390 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.390 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.340 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.320 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.300 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.270 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.240 | Inavolisib | — uncovered |
| HYPOXIA | 0.230 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.190 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.180 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.170 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.160 | Inavolisib | — uncovered |
| COMPLEMENT | 0.150 | Inavolisib | — uncovered |
| APOPTOSIS | 0.110 | Idelalisib | — uncovered |